Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary Objective:

To evaluate safety (4 weeks)

Secondary Objectives:

• To evaluate the long-term safety (12 weeks)

• To evaluate the efficacy

• To characterize the pharmacokinetic profile

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Fexofenadine

Criteria

Inclusion criteria:

• Aged 6 months through 11 years

• Patients with atopic dermatitis

Exclusion criteria:

• Main itching scores are 4 or less than 2 on last three consecutive days before registration.

• Patients who have itching only on face, head, or diaper area.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.